Beijing Hotgen Biotech Co., Ltd（688068.SH）released an announcement on July 6, the company intends to use its own funds together with Qingdao Chuangjing Private Equity Fund Management Co., Hangzhou Bioer Technology Co.,Ltd, Anhui Yaoan Investment Group Co. and Shaoxing Guochuang Zhende Medical (603301) Industry Phase I Equity Investment Partnership (Limited Partnership) co-finance and participate in the investment in Tristar Conrad. The proposed investment fund size of 475 million CNY, the company intends to contribute 200 million CNY with its own funds, the proportion of contribution is 42.11%.

It is reported that the name of the fund is Chuangjing Kangrun Venture Capital Partnership (Limited Partnership) (specific name to be approved by the business registration), and the fund manager is Qingdao Chuangjing Private Equity Fund Management Co.